$38.17 +0.26 (%) Acadia Pharmaceuticals Inc - NASDAQ

Aug. 28, 2015 | 04:00 PM

Partner Headlines

  1. Why Piper Jaffray Is Upgrading Acadia Pharmaceuticals After A 25% Decline

    Benzinga | Aug. 27, 2015 | 15:06PM EST
  2. Acadia Pharma May No Longer Be A Buy Ahead Of NDA Filing

    Benzinga | Aug. 7, 2015 | 13:27PM EST
  3. Stocks Easing Off Day's Lows; Caesarstone Rebounds

    IBD | Aug. 7, 2015 | 13:00PM EST
  4. Andreas Halvorsen Increases Stake in Esperion Therapeutics

    GuruFocus | Jun. 30, 2015 | 00:18AM EST
  5. Viking Global Liked AIG, Google, Actavis, Illumina And Cheniere Energy Last Quarter

    Benzinga | May. 18, 2015 | 13:38PM EST
  6. Benzinga's Top Initiations

    Benzinga | Apr. 16, 2015 | 09:45AM EST
  7. Acadia Will Outperform, Worth $48/Share Says Leerink

    Benzinga | Apr. 16, 2015 | 09:39AM EST
  8. Leerink Swann Initiates ACADIA Pharmaceuticals At Outperform

    Benzinga | Apr. 16, 2015 | 08:26AM EST
  9. Cowen Analyst Likes Intercept Pharmaceuticals, ACADIA Pharmaceuticals And Raptor Pharmaceutical

    Benzinga | Feb. 1, 2015 | 12:54PM EST
  10. Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 2

    Benzinga | Jan. 12, 2015 | 11:03AM EST
  11. Benzinga's Top Initiations

    Benzinga | Nov. 21, 2014 | 08:21AM EST
  12. Earnings Scheduled For November 10, 2014

    Benzinga | Nov. 10, 2014 | 05:36AM EST
  13. Benzinga's Volume Movers

    Benzinga | Sep. 2, 2014 | 10:25AM EST
  14. ACADIA Pharmaceuticals Announces Stephen Davis As Executive VP, CFO And Chief Business Officer

    Benzinga | Jul. 15, 2014 | 09:01AM EST
  15. 4 Biotech Stocks Worth A Look Ahead Of FDA Approvals

    Benzinga | Jul. 3, 2014 | 10:36AM EST
  16. Morning Lowers for Mar. 5, 2014: XOMA, USU, CSIQ, AUDC, RATE

    Benzinga | Mar. 5, 2014 | 10:14AM EST
  17. Top Stocks Of 2013 Run Gamut: Solar, Drugs, Tech, TV

    IBD | Jan. 2, 2014 | 18:59PM EST
  18. ACADIA Initiates Phase II Trial with Pimavanserin for Alzheimer's Disease Psychosis

    Benzinga | Nov. 14, 2013 | 09:19AM EST
  19. ACADIA Announces Publication of Pivotal Phase III Parkinson's Disease Psychosis Trial with Pimavanserin

    Benzinga | Nov. 1, 2013 | 06:01AM EST
  20. Benzinga's Volume Movers

    Benzinga | Oct. 10, 2013 | 10:33AM EST
  21. Benzinga's Top Pre-Market Gainers

    Benzinga | Oct. 10, 2013 | 08:16AM EST
  22. UPDATE: MLV & Co. Downgrades ACADIA Pharmaceuticals on Valuation

    Benzinga | Aug. 7, 2013 | 08:56AM EST
  23. Benzinga's Top Downgrades

    Benzinga | Aug. 7, 2013 | 07:45AM EST
  24. Acadia Pharma Announces $86M Equity Financing

    Benzinga | Dec. 12, 2012 | 02:05AM EST
  25. Benzinga's Top Pre-Market Losers

    Benzinga | Nov. 28, 2012 | 01:16AM EST
  26. ACADIA Pharmaceuticals Option Volume Spikes

    SchaeffersResearch | Nov. 27, 2012 | 10:36AM EST
  27. Acadia Pharma Rockets Higher on Study Results

    Benzinga | Nov. 27, 2012 | 09:44AM EST
  28. Top Narrow Based Indexes For November 27, 2012

    Benzinga | Nov. 27, 2012 | 03:38AM EST
  29. Stocks Hitting 52-Week Highs

    Benzinga | Nov. 27, 2012 | 03:06AM EST
  30. Morning Market Movers

    Benzinga | Nov. 27, 2012 | 02:49AM EST
  31. Benzinga's Top Pre-Market Gainers

    Benzinga | Nov. 27, 2012 | 01:13AM EST
  32. ACADIA's Pimavanserin Meets Primary and Key Secondary Endpoints in Pivotal Phase III Parkinson's Disease Psychosis Trial

    Benzinga | Nov. 27, 2012 | 00:27AM EST
  33. ACADIA Pharmaceuticals Inc. Reports Operating Results (10-Q)

    GuruFocus | Nov. 5, 2012 | 11:11AM EST
  34. Stocks Hitting 52-Week Highs

    Benzinga | Sep. 19, 2012 | 04:23AM EST
  35. Benzinga's Top Pre-Market Gainers

    Benzinga | Sep. 17, 2012 | 02:14AM EST
  36. Coinstar, Supervalu Among Stocks Down on Above-average Volume Friday

    FoxBusiness | Jul. 13, 2012 | 06:31AM EST
  37. From Earlier, ACADIA Pharmaceuticals Reports Promising Effects of Pimavanserin in Preclinical Model of Alzheimer's Disease Psychosis

    Benzinga | Jul. 9, 2012 | 03:21AM EST
  38. Earnings Scheduled For March 6

    Benzinga | Mar. 5, 2012 | 20:58PM EST
Trading Center
×

You are using adblocking software

Want access to all of Investopedia? Add us to your “whitelist”
so you'll never miss a feature!